title: Intensive induction therapy with behenoyl, cytosine arabinoside, daunorubicin, and 6-mercaptopurine followed by intensive consolidation with mitoxantrone, etoposide, vincristine, and intermediate-dose continuous cytarabine (M-85 protocol) for adult acute myelogenous leukemia.
authors.affiliation: First Department of Internal Medicine, Nagoya University School of Medicine, Aichi Shokuin Hospital, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Ohno
authors.forename: S
authors.initials: S
authors.lastname: Yokomaku
authors.forename: M
authors.initials: M
authors.lastname: Okumara
authors.forename: M
authors.initials: M
authors.lastname: Tanimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Morishita
authors.forename: Y
authors.initials: Y
authors.lastname: Morishima
authors.forename: Y
authors.initials: Y
authors.lastname: Kodera
authors.forename: H
authors.initials: H
authors.lastname: Saito
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007239:Infections / Q000209:etiology; D007564:Japan / Q000453:epidemiology; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009503:Neutropenia / Q000139:chemically induced; D012074:Remission Induction; D015996:Survival Rate